Home Blog Page 385

Internships Take Centre Stage as Students Prioritise Career Outcomes in Higher Education Choices


SINGAPORE – Media OutReach Newswire – 4 May 2026 – As students increasingly evaluate higher education options through the lens of employability, internships have emerged as a critical factor influencing decision-making, reflecting a broader shift towards experience-based learning. Recent findings from Singapore’s Graduate Employment Survey show that employment outcomes for graduates from autonomous universities and the private education sector are closely tracked, with data generally collected approximately six months after graduation to capture early career transitions.

While overall employment rates remain relatively resilient, education and labour market observers note that graduates are increasingly expected to demonstrate practical experience in addition to academic qualifications. Industry commentary linked to the survey highlights that internships and prior work exposure can play a key role in improving employability, particularly in a tighter job market.

Internships as a Bridge Between Education and Employment

Internships are widely regarded as a critical bridge between academic learning and professional employment. They provide students with opportunities to develop workplace competencies, understand organisational environments and build networks that can support job placement after graduation. With Graduate Employment Survey data indicating increased competition for full-time roles, early exposure to industry has become an important differentiator for students entering the workforce.

Embedding Internships into the Student Experience

The Singapore Institute of Management (SIM) has incorporated internships as a core component of its employability strategy through its Career Connect department. Internships are positioned as a key pathway that “bridge students and graduates into the realities of the working world,” allowing them to apply academic knowledge in real business environments.

SIM works with a network of companies ranging from small and medium enterprises to multinational organisations, providing students with access to internship opportunities across sectors.

Students may source internships independently or tap into structured opportunities within SIM’s ecosystem, including in-house placements through initiatives such as the Talent Development Programme.

Technology Enabled Access to Internship Opportunities

To support access at scale, SIM has introduced CareerSense, a digital platform that aggregates internship listings, job opportunities and career events into a single interface. Through this platform, students can connect with employers, explore opportunities and participate in career development activities, reflecting a broader shift towards digital career services in higher education.

Recognising the Value of Internship Participation

SIM has also introduced initiatives to recognise student participation in internships and experiential learning. The SIM60 Work-Integrated Learning for Life WILL Award highlights the role of internships in developing both technical and transferable skills such as communication, adaptability and problem solving. Such initiatives reflect a wider industry view that structured work experience is an increasingly important component of graduate readiness.

A Growing Expectation Among Students

The emphasis on internships reflects a broader shift in student priorities. As employment outcomes become more closely tied to educational choices, students are seeking clearer pathways from classroom learning to career opportunities.

With Graduate Employment Survey data pointing to a more competitive hiring environment, institutions that provide strong access to internships and industry engagement are likely to play a more significant role in shaping graduate success.

References

  1. Ministry of Education Singapore Graduate Employment Survey – https://data.gov.sg/datasets?resultId=d_3c55210de27fcccda2ed0c63fdd2b352&topics=education
  2. Private Education Employment Survey – https://www.ssg.gov.sg/resources/pei/pei-ges/private-education-institution-graduate-employment-survey-2024-2025
  3. Full-time employment opportunity falls to 79.5% for fresh graduates in S’pore – https://hrsea.economictimes.indiatimes.com/news/industry/full-time-employment-opportunity-falls-to-79-5-for-fresh-graduates-in-spore-survey-finds/118531408?
  4. SIM Career Service – https://www.sim.edu.sg/degrees-diplomas/life-at-sim/career-services
  5. SIM Internship & Employment Opportunities – https://www.sim.edu.sg/alumni/internship-and-employment-opportunities

Hashtag: #SIMGlobalEducation #SIMGE #GlobalEducation #InternationalDegree #CareerReady #FutureSkills

The issuer is solely responsible for the content of this announcement.

About SIM Global Education

SIM Global Education (SIM GE) is a leading private education institution in Singapore and the region. We offer more than 140 academic programmes ranging from diplomas and graduate diploma programmes to bachelor’s and master’s degree programmes with some of the world’s most reputable universities from Australia, Canada, Europe, United Kingdom, and the United States. SIM GE’s cohort is made up of 17,000 full- and part-time students and adult learners, of which approximately 41% are international students hailing from over 50 countries.

SIM GE’s holistic learning approach and culturally diverse learning environment aim to equip students with knowledge, industry skills and employability competencies, as well as a global perspective to succeed as future leaders in a fast-changing, technologically driven world.

For more information on SIM Global Education, visit

COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++, UK’s No.1 Bestseller Sunscreen with CPNP Certification, Solidifies Leadership in Thailand

4.9-Star Rating on Shopee and TikTok Shop Thailand | 16,000+ Verified Reviews

Key Highlights

  • Ranked #1 in Sunscreen category on Amazon UK (*April 14, 2026)
  •  A European favorite, certified under EU CPNP – one of the world’s strictest cosmetic standards
  • 4.9-star rating on Shopee and TikTok Shop Thailand from 16,000+ verified reviews (*as of April 29, 2026)
  • Lightweight, zero white cast, optimized for Thailand’s hot-humid climate
  • Thai FDA Registration No. 10-2-6700013181

BANGKOK, May 4, 2026 /PRNewswire/ — COSRX, a leading Korean beauty brand, announced today that its Ultra-Light Invisible Sunscreen SPF50 PA++++ has secured the No.1 position in the Sunscreen category in the Amazon UK as of April 14, 2026. Beyond its top ranking, the product has generated strong demand as a European favorite, while reinforcing its market leadership in Thailand with a 4.9-star rating on Shopee and TikTok Shop Thailand from over 16,000 verified consumers.

COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++,  UK's No.1 Bestseller Sunscreen with CPNP Certification,  Solidifies Leadership in Thailand
COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++, UK’s No.1 Bestseller Sunscreen with CPNP Certification, Solidifies Leadership in Thailand

What is CPNP and Why Does It Matter to Thai Consumers?

The Cosmetic Products Notification Portal (CPNP) is the European Union’s mandatory cosmetic product notification system, requiring rigorous safety assessment before market entry. It is widely regarded as one of the world’s strictest cosmetic regulatory frameworks.

Following the recent UV protection issue, Thai consumers have voiced growing skepticism about the actual UV protection efficacy of the sunscreens. COSRX addresses these concerns with a scientifically validated solution that has become a European favorite – conquering a region renowned for the highest global standards in sun protection.

Why is COSRX Sunscreen Ideal for Thailand’s Climate?

According to the Thai Meteorological Department, the average UV Index in Bangkok measures 11+ (Extreme) year-round, while major urban centers like Khon Kaen, Hat Yai, and Nakhon Ratchasima experience similarly intense UV exposure throughout the year.

COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ is engineered for these conditions:

  • Watery, lightweight texture that absorbs quickly without stickiness
  • Aloe Vera and Witch Hazel soothe the skin
  • Zero white cast – suitable for all skin tones
  • Clinically proven cooling effect that instantly reduces skin heat and redness by 86.32%

Who Recommends COSRX in Thailand?

The product has been endorsed by Thailand’s most authoritative skincare voices:

  • @ingck – Recognized for ingredient-focused skincare reviews and hands-on testing
  • @eb.bahboh – A highly respected medical doctor and creator offering science-backed dermatological expertise

Both have confirmed the product’s efficacy, protection, and suitability for Thai skin after extensive personal use.

Consumers in Thailand can explore COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ and the broader COSRX suncare range through the brand’s official stores on TikTok Shop Thailand and Shopee Thailand. Purchasing through official channels helps ensure product authenticity and access to the latest brand information.

Experience the UK’s No. 1 and Europe’s favorite sunscreen choice and explore the full COSRX range at the Official TikTok Shop Thailand and Official Shopee. COSRX is also on TikTok + Shopee.

Frequently Asked Questions (FAQ)

Q1. What does EU CPNP registration mean?

A1. EU CPNP registration means the product has been notified through the European Union’s Cosmetic Products Notification Portal before being placed on the EU market. It is part of the EU’s regulatory framework for cosmetics.

Q2. What proof supports the product’s consumer popularity in Thailand?

A2. As of April 29, 2026, the product holds a 4.9-star rating across Shopee and TikTok Shop Thailand, with more than 16,000 verified reviews.

Q3. Why is COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ suitable for Thailand’s climate?

A3. It delivers uncompromising, heavy-duty UV defense (SPF50 PA++++) to combat Thailand’s intense sun, without sacrificing daily comfort. Even in hot and humid weather, its watery, lightweight texture absorbs quickly, feels breathable on the skin, and leaves absolutely no white cast.

Q4. Does this sunscreen leave a white cast?

A4. No. COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ is designed to deliver an invisible finish without leaving a noticeable white cast on skin.

Q5. Is this product registered in Thailand?

A5. Yes. Thai FDA Registration No. 10-2-6700013181.

Q6. Where can consumers buy authentic COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ in Thailand?

A6. Authentic products are available through COSRX’s official stores on Shopee Thailand and TikTok Shop Thailand.

About COSRX

Rooted in science and driven by results, COSRX is a global beauty brand known for its high performance yet affordable formulations that target real skin concerns with minimal ingredients and maximum efficacy. Trusted by skincare lovers worldwide, COSRX delivers visible results through carefully selected actives in concentrated doses. Discover its award-winning lineup at retailers including COSRX.com, Shopee, TikTok Shop, Beautrium, Watsons and EVEANDBOY. Follow @cosrx.thailand on Instagram and @cosrx.th on TikTok for the latest product drops, tips, and trends.

COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++, UK’s No.1 Bestseller Sunscreen with CPNP Certification, Solidifies Leadership in Thailand

4.9-Star Rating on Shopee and TikTok Shop Thailand | 16,000+ Verified Reviews

Key Highlights

  • Ranked #1 in Sunscreen category on Amazon UK (*April 14, 2026)
  •  A European favorite, certified under EU CPNP – one of the world’s strictest cosmetic standards
  • 4.9-star rating on Shopee and TikTok Shop Thailand from 16,000+ verified reviews (*as of April 29, 2026)
  • Lightweight, zero white cast, optimized for Thailand’s hot-humid climate
  • Thai FDA Registration No. 10-2-6700013181

BANGKOK, May 4, 2026 /PRNewswire/ — COSRX, a leading Korean beauty brand, announced today that its Ultra-Light Invisible Sunscreen SPF50 PA++++ has secured the No.1 position in the Sunscreen category in the Amazon UK as of April 14, 2026. Beyond its top ranking, the product has generated strong demand as a European favorite, while reinforcing its market leadership in Thailand with a 4.9-star rating on Shopee and TikTok Shop Thailand from over 16,000 verified consumers.

COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++,  UK's No.1 Bestseller Sunscreen with CPNP Certification,  Solidifies Leadership in Thailand
COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++, UK’s No.1 Bestseller Sunscreen with CPNP Certification, Solidifies Leadership in Thailand

What is CPNP and Why Does It Matter to Thai Consumers?

The Cosmetic Products Notification Portal (CPNP) is the European Union’s mandatory cosmetic product notification system, requiring rigorous safety assessment before market entry. It is widely regarded as one of the world’s strictest cosmetic regulatory frameworks.

Following the recent UV protection issue, Thai consumers have voiced growing skepticism about the actual UV protection efficacy of the sunscreens. COSRX addresses these concerns with a scientifically validated solution that has become a European favorite – conquering a region renowned for the highest global standards in sun protection.

Why is COSRX Sunscreen Ideal for Thailand’s Climate?

According to the Thai Meteorological Department, the average UV Index in Bangkok measures 11+ (Extreme) year-round, while major urban centers like Khon Kaen, Hat Yai, and Nakhon Ratchasima experience similarly intense UV exposure throughout the year.

COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ is engineered for these conditions:

  • Watery, lightweight texture that absorbs quickly without stickiness
  • Aloe Vera and Witch Hazel soothe the skin
  • Zero white cast – suitable for all skin tones
  • Clinically proven cooling effect that instantly reduces skin heat and redness by 86.32%

Who Recommends COSRX in Thailand?

The product has been endorsed by Thailand’s most authoritative skincare voices:

  • @ingck – Recognized for ingredient-focused skincare reviews and hands-on testing
  • @eb.bahboh – A highly respected medical doctor and creator offering science-backed dermatological expertise

Both have confirmed the product’s efficacy, protection, and suitability for Thai skin after extensive personal use.

Consumers in Thailand can explore COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ and the broader COSRX suncare range through the brand’s official stores on TikTok Shop Thailand and Shopee Thailand. Purchasing through official channels helps ensure product authenticity and access to the latest brand information.

Experience the UK’s No. 1 and Europe’s favorite sunscreen choice and explore the full COSRX range at the Official TikTok Shop Thailand and Official Shopee. COSRX is also on TikTok + Shopee.

Frequently Asked Questions (FAQ)

Q1. What does EU CPNP registration mean?

A1. EU CPNP registration means the product has been notified through the European Union’s Cosmetic Products Notification Portal before being placed on the EU market. It is part of the EU’s regulatory framework for cosmetics.

Q2. What proof supports the product’s consumer popularity in Thailand?

A2. As of April 29, 2026, the product holds a 4.9-star rating across Shopee and TikTok Shop Thailand, with more than 16,000 verified reviews.

Q3. Why is COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ suitable for Thailand’s climate?

A3. It delivers uncompromising, heavy-duty UV defense (SPF50 PA++++) to combat Thailand’s intense sun, without sacrificing daily comfort. Even in hot and humid weather, its watery, lightweight texture absorbs quickly, feels breathable on the skin, and leaves absolutely no white cast.

Q4. Does this sunscreen leave a white cast?

A4. No. COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ is designed to deliver an invisible finish without leaving a noticeable white cast on skin.

Q5. Is this product registered in Thailand?

A5. Yes. Thai FDA Registration No. 10-2-6700013181.

Q6. Where can consumers buy authentic COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ in Thailand?

A6. Authentic products are available through COSRX’s official stores on Shopee Thailand and TikTok Shop Thailand.

About COSRX

Rooted in science and driven by results, COSRX is a global beauty brand known for its high performance yet affordable formulations that target real skin concerns with minimal ingredients and maximum efficacy. Trusted by skincare lovers worldwide, COSRX delivers visible results through carefully selected actives in concentrated doses. Discover its award-winning lineup at retailers including COSRX.com, Shopee, TikTok Shop, Beautrium, Watsons and EVEANDBOY. Follow @cosrx.thailand on Instagram and @cosrx.th on TikTok for the latest product drops, tips, and trends.

COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++, UK’s No.1 Bestseller Sunscreen with CPNP Certification, Solidifies Leadership in Thailand

4.9-Star Rating on Shopee and TikTok Shop Thailand | 16,000+ Verified Reviews

Key Highlights

  • Ranked #1 in Sunscreen category on Amazon UK (*April 14, 2026)
  •  A European favorite, certified under EU CPNP – one of the world’s strictest cosmetic standards
  • 4.9-star rating on Shopee and TikTok Shop Thailand from 16,000+ verified reviews (*as of April 29, 2026)
  • Lightweight, zero white cast, optimized for Thailand’s hot-humid climate
  • Thai FDA Registration No. 10-2-6700013181

BANGKOK, May 4, 2026 /PRNewswire/ — COSRX, a leading Korean beauty brand, announced today that its Ultra-Light Invisible Sunscreen SPF50 PA++++ has secured the No.1 position in the Sunscreen category in the Amazon UK as of April 14, 2026. Beyond its top ranking, the product has generated strong demand as a European favorite, while reinforcing its market leadership in Thailand with a 4.9-star rating on Shopee and TikTok Shop Thailand from over 16,000 verified consumers.

COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++,  UK's No.1 Bestseller Sunscreen with CPNP Certification,  Solidifies Leadership in Thailand
COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++, UK’s No.1 Bestseller Sunscreen with CPNP Certification, Solidifies Leadership in Thailand

What is CPNP and Why Does It Matter to Thai Consumers?

The Cosmetic Products Notification Portal (CPNP) is the European Union’s mandatory cosmetic product notification system, requiring rigorous safety assessment before market entry. It is widely regarded as one of the world’s strictest cosmetic regulatory frameworks.

Following the recent UV protection issue, Thai consumers have voiced growing skepticism about the actual UV protection efficacy of the sunscreens. COSRX addresses these concerns with a scientifically validated solution that has become a European favorite – conquering a region renowned for the highest global standards in sun protection.

Why is COSRX Sunscreen Ideal for Thailand’s Climate?

According to the Thai Meteorological Department, the average UV Index in Bangkok measures 11+ (Extreme) year-round, while major urban centers like Khon Kaen, Hat Yai, and Nakhon Ratchasima experience similarly intense UV exposure throughout the year.

COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ is engineered for these conditions:

  • Watery, lightweight texture that absorbs quickly without stickiness
  • Aloe Vera and Witch Hazel soothe the skin
  • Zero white cast – suitable for all skin tones
  • Clinically proven cooling effect that instantly reduces skin heat and redness by 86.32%

Who Recommends COSRX in Thailand?

The product has been endorsed by Thailand’s most authoritative skincare voices:

  • @ingck – Recognized for ingredient-focused skincare reviews and hands-on testing
  • @eb.bahboh – A highly respected medical doctor and creator offering science-backed dermatological expertise

Both have confirmed the product’s efficacy, protection, and suitability for Thai skin after extensive personal use.

Consumers in Thailand can explore COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ and the broader COSRX suncare range through the brand’s official stores on TikTok Shop Thailand and Shopee Thailand. Purchasing through official channels helps ensure product authenticity and access to the latest brand information.

Experience the UK’s No. 1 and Europe’s favorite sunscreen choice and explore the full COSRX range at the Official TikTok Shop Thailand and Official Shopee. COSRX is also on TikTok + Shopee.

Frequently Asked Questions (FAQ)

Q1. What does EU CPNP registration mean?

A1. EU CPNP registration means the product has been notified through the European Union’s Cosmetic Products Notification Portal before being placed on the EU market. It is part of the EU’s regulatory framework for cosmetics.

Q2. What proof supports the product’s consumer popularity in Thailand?

A2. As of April 29, 2026, the product holds a 4.9-star rating across Shopee and TikTok Shop Thailand, with more than 16,000 verified reviews.

Q3. Why is COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ suitable for Thailand’s climate?

A3. It delivers uncompromising, heavy-duty UV defense (SPF50 PA++++) to combat Thailand’s intense sun, without sacrificing daily comfort. Even in hot and humid weather, its watery, lightweight texture absorbs quickly, feels breathable on the skin, and leaves absolutely no white cast.

Q4. Does this sunscreen leave a white cast?

A4. No. COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ is designed to deliver an invisible finish without leaving a noticeable white cast on skin.

Q5. Is this product registered in Thailand?

A5. Yes. Thai FDA Registration No. 10-2-6700013181.

Q6. Where can consumers buy authentic COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ in Thailand?

A6. Authentic products are available through COSRX’s official stores on Shopee Thailand and TikTok Shop Thailand.

About COSRX

Rooted in science and driven by results, COSRX is a global beauty brand known for its high performance yet affordable formulations that target real skin concerns with minimal ingredients and maximum efficacy. Trusted by skincare lovers worldwide, COSRX delivers visible results through carefully selected actives in concentrated doses. Discover its award-winning lineup at retailers including COSRX.com, Shopee, TikTok Shop, Beautrium, Watsons and EVEANDBOY. Follow @cosrx.thailand on Instagram and @cosrx.th on TikTok for the latest product drops, tips, and trends.

COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++, UK’s No.1 Bestseller Sunscreen with CPNP Certification, Solidifies Leadership in Thailand

4.9-Star Rating on Shopee and TikTok Shop Thailand | 16,000+ Verified Reviews

Key Highlights

  • Ranked #1 in Sunscreen category on Amazon UK (*April 14, 2026)
  •  A European favorite, certified under EU CPNP – one of the world’s strictest cosmetic standards
  • 4.9-star rating on Shopee and TikTok Shop Thailand from 16,000+ verified reviews (*as of April 29, 2026)
  • Lightweight, zero white cast, optimized for Thailand’s hot-humid climate
  • Thai FDA Registration No. 10-2-6700013181

BANGKOK, May 4, 2026 /PRNewswire/ — COSRX, a leading Korean beauty brand, announced today that its Ultra-Light Invisible Sunscreen SPF50 PA++++ has secured the No.1 position in the Sunscreen category in the Amazon UK as of April 14, 2026. Beyond its top ranking, the product has generated strong demand as a European favorite, while reinforcing its market leadership in Thailand with a 4.9-star rating on Shopee and TikTok Shop Thailand from over 16,000 verified consumers.

COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++,  UK's No.1 Bestseller Sunscreen with CPNP Certification,  Solidifies Leadership in Thailand
COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++, UK’s No.1 Bestseller Sunscreen with CPNP Certification, Solidifies Leadership in Thailand

What is CPNP and Why Does It Matter to Thai Consumers?

The Cosmetic Products Notification Portal (CPNP) is the European Union’s mandatory cosmetic product notification system, requiring rigorous safety assessment before market entry. It is widely regarded as one of the world’s strictest cosmetic regulatory frameworks.

Following the recent UV protection issue, Thai consumers have voiced growing skepticism about the actual UV protection efficacy of the sunscreens. COSRX addresses these concerns with a scientifically validated solution that has become a European favorite – conquering a region renowned for the highest global standards in sun protection.

Why is COSRX Sunscreen Ideal for Thailand’s Climate?

According to the Thai Meteorological Department, the average UV Index in Bangkok measures 11+ (Extreme) year-round, while major urban centers like Khon Kaen, Hat Yai, and Nakhon Ratchasima experience similarly intense UV exposure throughout the year.

COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ is engineered for these conditions:

  • Watery, lightweight texture that absorbs quickly without stickiness
  • Aloe Vera and Witch Hazel soothe the skin
  • Zero white cast – suitable for all skin tones
  • Clinically proven cooling effect that instantly reduces skin heat and redness by 86.32%

Who Recommends COSRX in Thailand?

The product has been endorsed by Thailand’s most authoritative skincare voices:

  • @ingck – Recognized for ingredient-focused skincare reviews and hands-on testing
  • @eb.bahboh – A highly respected medical doctor and creator offering science-backed dermatological expertise

Both have confirmed the product’s efficacy, protection, and suitability for Thai skin after extensive personal use.

Consumers in Thailand can explore COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ and the broader COSRX suncare range through the brand’s official stores on TikTok Shop Thailand and Shopee Thailand. Purchasing through official channels helps ensure product authenticity and access to the latest brand information.

Experience the UK’s No. 1 and Europe’s favorite sunscreen choice and explore the full COSRX range at the Official TikTok Shop Thailand and Official Shopee. COSRX is also on TikTok + Shopee.

Frequently Asked Questions (FAQ)

Q1. What does EU CPNP registration mean?

A1. EU CPNP registration means the product has been notified through the European Union’s Cosmetic Products Notification Portal before being placed on the EU market. It is part of the EU’s regulatory framework for cosmetics.

Q2. What proof supports the product’s consumer popularity in Thailand?

A2. As of April 29, 2026, the product holds a 4.9-star rating across Shopee and TikTok Shop Thailand, with more than 16,000 verified reviews.

Q3. Why is COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ suitable for Thailand’s climate?

A3. It delivers uncompromising, heavy-duty UV defense (SPF50 PA++++) to combat Thailand’s intense sun, without sacrificing daily comfort. Even in hot and humid weather, its watery, lightweight texture absorbs quickly, feels breathable on the skin, and leaves absolutely no white cast.

Q4. Does this sunscreen leave a white cast?

A4. No. COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ is designed to deliver an invisible finish without leaving a noticeable white cast on skin.

Q5. Is this product registered in Thailand?

A5. Yes. Thai FDA Registration No. 10-2-6700013181.

Q6. Where can consumers buy authentic COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ in Thailand?

A6. Authentic products are available through COSRX’s official stores on Shopee Thailand and TikTok Shop Thailand.

About COSRX

Rooted in science and driven by results, COSRX is a global beauty brand known for its high performance yet affordable formulations that target real skin concerns with minimal ingredients and maximum efficacy. Trusted by skincare lovers worldwide, COSRX delivers visible results through carefully selected actives in concentrated doses. Discover its award-winning lineup at retailers including COSRX.com, Shopee, TikTok Shop, Beautrium, Watsons and EVEANDBOY. Follow @cosrx.thailand on Instagram and @cosrx.th on TikTok for the latest product drops, tips, and trends.

XtalPi -Enabled PharmaEngine PEP08 Achieves Enrollment Milestone, with Second Synthetic Lethality Program Underway

SHENZHEN, China, May 4, 2026 /PRNewswire/ — XtalPi (2228.HK), a leading AI- and robotics-powered innovation platform, today announced dual breakthroughs in its strategic partnership with PharmaEngine (4162.TWO) PEP08, a next-generation PRMT5 inhibitor discovered via XtalPi’s platform, has successfully begun enrollments in a Phase I solid tumor trial, achieving a new clinical milestone. Built upon the success of PEP08 at the drug discovery stage, the two companies initiated a second project, targeting a different undisclosed synthetic lethality mechanism.

PEP08 received clinical clearance in June 2025 and is currently in Phase I evaluation for solid tumors in Australia and the Taiwan region. The enrollment milestone underscores XtalPi’s ability to deliver differentiated molecules with strong drug-like properties, while demonstrating the program’s steady clinical advancement.

Leveraging XtalPi’s integrated quantum physics-, AI-, and robotics-powered platform, PEP08 was designed to overcome the dose-limiting hematological toxicities seen with first-generation PRMT5 inhibitors. The molecule exploits an innovative MTA-cooperative binding mode to specifically target MTAP-deleted tumors—a genomic alteration found in 10-15% of all human cancers, with higher frequencies observed in NSCLC, pancreatic cancer, glioblastoma, and more. Preclinical data presented at 2025 AACR show PEP08 achieving superior efficacy compared to other clinical-stage MTA-cooperative PRMT5 inhibitors across multiple MTAP-deleted tumor models, supporting a potential best-in-class profile.

Driven by the success of PEP08 at the drug discovery stage, the partnership expanded into a second project. By combining PharmaEngine’s deep oncology expertise with XtalPi’s AI and robotics molecular design engine, the duo aims to capture additional market share in the synthetic lethality space.

Synthetic lethality is widely recognized as challenging yet highly promising frontier in oncology. According to Globocan and industry data, the global market is expected to grow from $4.2 billion to $17.6 billion by 2033, at a 17.3% CAGR. In recent years, several early-stage licensing deals in this space have exceeded $1 billion USD, further underscoring the immense clinical value and commercial appetite for this category.

The clinical advancement of PEP08 and the ongoing collaboration of the second project serve as a dual validation of XtalPi’s AI+robotics discovery engine. By repeatedly meeting rigorous benchmarks in complex target spaces, XtalPi has built a reproducible innovation model that turns deep know-how into high-value clinical assets. Underpinned by a milestone-sharing structure, this model tightly aligns the platform’s evolution with clinical success, quickly translating biological insights into tangible impact for partners and patients around the world.

Dr. Shuhao Wen, Chairman of XtalPi commented, “The clinical progress of PEP08 and the ongoing collaboration of the second project are testaments to the synergy between our teams, and highlights the reliability of XtalPi’s R&D platform in tackling complex targets. We look forward to further applying this model to deliver high-quality pipeline assets for our partners and generate sustained value for our shareholders.”

“PharmaEngine has been advancing its R&D capabilities, and our collaboration with XtalPi exemplifies our ability to harness innovative technologies to propel next-generation discoveries in precision oncology,” said Dr. Hong-Ren Wang, CEO and President of PharmaEngine. “XtalPi’s R&D platform played a key role in the early-stage discovery of PEP08, providing a robust foundation for its clinical entry. Our collaboration of PEP08 and the second project demonstrates our ongoing efforts to advance cancer treatment development worldwide.

About PharmaEngine, Inc.

PharmaEngine, Inc. (4162.TWO), headquartered in Taipei, began operations in February 2003. PharmaEngine focuses on new drug development by adopting “Virtual Pharmaceutical Company Business Model”. PharmaEngine has one commercial product, ONIVYDE®, which is currently approved for the treatment of adult patients with metastatic pancreatic adenocarcinoma. In addition, PharmaEngine is advancing PEP07 (CHK1 inhibitor) and PEP08 (MTA-collaborative PRMT5 inhibitor) through Phase I clinical trials. Leveraging its extensive experience in drug development and project management, the Company aims to continue expanding its pipeline. PharmaEngine also pursues international collaborations and out-licensing agreements to accelerate the discovery, development, and commercialization of novel cancer therapies.

About XtalPi

XtalPi Holdings Limited (XtalPi, 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.

XtalPi -Enabled PharmaEngine PEP08 Achieves Enrollment Milestone, with Second Synthetic Lethality Program Underway

SHENZHEN, China, May 4, 2026 /PRNewswire/ — XtalPi (2228.HK), a leading AI- and robotics-powered innovation platform, today announced dual breakthroughs in its strategic partnership with PharmaEngine (4162.TWO) PEP08, a next-generation PRMT5 inhibitor discovered via XtalPi’s platform, has successfully begun enrollments in a Phase I solid tumor trial, achieving a new clinical milestone. Built upon the success of PEP08 at the drug discovery stage, the two companies initiated a second project, targeting a different undisclosed synthetic lethality mechanism.

PEP08 received clinical clearance in June 2025 and is currently in Phase I evaluation for solid tumors in Australia and the Taiwan region. The enrollment milestone underscores XtalPi’s ability to deliver differentiated molecules with strong drug-like properties, while demonstrating the program’s steady clinical advancement.

Leveraging XtalPi’s integrated quantum physics-, AI-, and robotics-powered platform, PEP08 was designed to overcome the dose-limiting hematological toxicities seen with first-generation PRMT5 inhibitors. The molecule exploits an innovative MTA-cooperative binding mode to specifically target MTAP-deleted tumors—a genomic alteration found in 10-15% of all human cancers, with higher frequencies observed in NSCLC, pancreatic cancer, glioblastoma, and more. Preclinical data presented at 2025 AACR show PEP08 achieving superior efficacy compared to other clinical-stage MTA-cooperative PRMT5 inhibitors across multiple MTAP-deleted tumor models, supporting a potential best-in-class profile.

Driven by the success of PEP08 at the drug discovery stage, the partnership expanded into a second project. By combining PharmaEngine’s deep oncology expertise with XtalPi’s AI and robotics molecular design engine, the duo aims to capture additional market share in the synthetic lethality space.

Synthetic lethality is widely recognized as challenging yet highly promising frontier in oncology. According to Globocan and industry data, the global market is expected to grow from $4.2 billion to $17.6 billion by 2033, at a 17.3% CAGR. In recent years, several early-stage licensing deals in this space have exceeded $1 billion USD, further underscoring the immense clinical value and commercial appetite for this category.

The clinical advancement of PEP08 and the ongoing collaboration of the second project serve as a dual validation of XtalPi’s AI+robotics discovery engine. By repeatedly meeting rigorous benchmarks in complex target spaces, XtalPi has built a reproducible innovation model that turns deep know-how into high-value clinical assets. Underpinned by a milestone-sharing structure, this model tightly aligns the platform’s evolution with clinical success, quickly translating biological insights into tangible impact for partners and patients around the world.

Dr. Shuhao Wen, Chairman of XtalPi commented, “The clinical progress of PEP08 and the ongoing collaboration of the second project are testaments to the synergy between our teams, and highlights the reliability of XtalPi’s R&D platform in tackling complex targets. We look forward to further applying this model to deliver high-quality pipeline assets for our partners and generate sustained value for our shareholders.”

“PharmaEngine has been advancing its R&D capabilities, and our collaboration with XtalPi exemplifies our ability to harness innovative technologies to propel next-generation discoveries in precision oncology,” said Dr. Hong-Ren Wang, CEO and President of PharmaEngine. “XtalPi’s R&D platform played a key role in the early-stage discovery of PEP08, providing a robust foundation for its clinical entry. Our collaboration of PEP08 and the second project demonstrates our ongoing efforts to advance cancer treatment development worldwide.

About PharmaEngine, Inc.

PharmaEngine, Inc. (4162.TWO), headquartered in Taipei, began operations in February 2003. PharmaEngine focuses on new drug development by adopting “Virtual Pharmaceutical Company Business Model”. PharmaEngine has one commercial product, ONIVYDE®, which is currently approved for the treatment of adult patients with metastatic pancreatic adenocarcinoma. In addition, PharmaEngine is advancing PEP07 (CHK1 inhibitor) and PEP08 (MTA-collaborative PRMT5 inhibitor) through Phase I clinical trials. Leveraging its extensive experience in drug development and project management, the Company aims to continue expanding its pipeline. PharmaEngine also pursues international collaborations and out-licensing agreements to accelerate the discovery, development, and commercialization of novel cancer therapies.

About XtalPi

XtalPi Holdings Limited (XtalPi, 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.

XtalPi -Enabled PharmaEngine PEP08 Achieves Enrollment Milestone, with Second Synthetic Lethality Program Underway

SHENZHEN, China, May 4, 2026 /PRNewswire/ — XtalPi (2228.HK), a leading AI- and robotics-powered innovation platform, today announced dual breakthroughs in its strategic partnership with PharmaEngine (4162.TWO) PEP08, a next-generation PRMT5 inhibitor discovered via XtalPi’s platform, has successfully begun enrollments in a Phase I solid tumor trial, achieving a new clinical milestone. Built upon the success of PEP08 at the drug discovery stage, the two companies initiated a second project, targeting a different undisclosed synthetic lethality mechanism.

PEP08 received clinical clearance in June 2025 and is currently in Phase I evaluation for solid tumors in Australia and the Taiwan region. The enrollment milestone underscores XtalPi’s ability to deliver differentiated molecules with strong drug-like properties, while demonstrating the program’s steady clinical advancement.

Leveraging XtalPi’s integrated quantum physics-, AI-, and robotics-powered platform, PEP08 was designed to overcome the dose-limiting hematological toxicities seen with first-generation PRMT5 inhibitors. The molecule exploits an innovative MTA-cooperative binding mode to specifically target MTAP-deleted tumors—a genomic alteration found in 10-15% of all human cancers, with higher frequencies observed in NSCLC, pancreatic cancer, glioblastoma, and more. Preclinical data presented at 2025 AACR show PEP08 achieving superior efficacy compared to other clinical-stage MTA-cooperative PRMT5 inhibitors across multiple MTAP-deleted tumor models, supporting a potential best-in-class profile.

Driven by the success of PEP08 at the drug discovery stage, the partnership expanded into a second project. By combining PharmaEngine’s deep oncology expertise with XtalPi’s AI and robotics molecular design engine, the duo aims to capture additional market share in the synthetic lethality space.

Synthetic lethality is widely recognized as challenging yet highly promising frontier in oncology. According to Globocan and industry data, the global market is expected to grow from $4.2 billion to $17.6 billion by 2033, at a 17.3% CAGR. In recent years, several early-stage licensing deals in this space have exceeded $1 billion USD, further underscoring the immense clinical value and commercial appetite for this category.

The clinical advancement of PEP08 and the ongoing collaboration of the second project serve as a dual validation of XtalPi’s AI+robotics discovery engine. By repeatedly meeting rigorous benchmarks in complex target spaces, XtalPi has built a reproducible innovation model that turns deep know-how into high-value clinical assets. Underpinned by a milestone-sharing structure, this model tightly aligns the platform’s evolution with clinical success, quickly translating biological insights into tangible impact for partners and patients around the world.

Dr. Shuhao Wen, Chairman of XtalPi commented, “The clinical progress of PEP08 and the ongoing collaboration of the second project are testaments to the synergy between our teams, and highlights the reliability of XtalPi’s R&D platform in tackling complex targets. We look forward to further applying this model to deliver high-quality pipeline assets for our partners and generate sustained value for our shareholders.”

“PharmaEngine has been advancing its R&D capabilities, and our collaboration with XtalPi exemplifies our ability to harness innovative technologies to propel next-generation discoveries in precision oncology,” said Dr. Hong-Ren Wang, CEO and President of PharmaEngine. “XtalPi’s R&D platform played a key role in the early-stage discovery of PEP08, providing a robust foundation for its clinical entry. Our collaboration of PEP08 and the second project demonstrates our ongoing efforts to advance cancer treatment development worldwide.

About PharmaEngine, Inc.

PharmaEngine, Inc. (4162.TWO), headquartered in Taipei, began operations in February 2003. PharmaEngine focuses on new drug development by adopting “Virtual Pharmaceutical Company Business Model”. PharmaEngine has one commercial product, ONIVYDE®, which is currently approved for the treatment of adult patients with metastatic pancreatic adenocarcinoma. In addition, PharmaEngine is advancing PEP07 (CHK1 inhibitor) and PEP08 (MTA-collaborative PRMT5 inhibitor) through Phase I clinical trials. Leveraging its extensive experience in drug development and project management, the Company aims to continue expanding its pipeline. PharmaEngine also pursues international collaborations and out-licensing agreements to accelerate the discovery, development, and commercialization of novel cancer therapies.

About XtalPi

XtalPi Holdings Limited (XtalPi, 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.